Back

Changes in physical performance after Fontan operation: a follow-up study

25 August 2023 (13:15 - 13:45)
Organised by: Logo
Congress Presentation Part of: Clinical performance of patients with adult congenital heart disease Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mrs Aida Luiza Ribeiro Turquetto

Heart Institute of the University of Sao Paulo (InCor), Sao Paulo (Brazil)

4 More presentations in this session

Presentation thumbnail
Decreased clinical performance in TGA-ASO patients after RVOT re-interventions; multicenter European collaboration
Mr L. Engele (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Safety of cardiopulmonary exercise testing in a large contemporary cohort of adults with congenital heart disease: implications on levels of test supervision
Doctor K. Krishnathasan (London, GB)
Abstract Slides Video
Presentation thumbnail
Clinical factors affecting survival in patients with congenitally corrected transposition of the great arteries: systemic review and meta-analysis.
Miss S. Nartowicz (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Blood and imaging biomarkers in the long-term follow-up of bicuspid aortic valve patients
Mr P. Hendriks (Rotterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical performance of patients with adult congenital heart disease

The Event

Event poster

ESC Congress 2023

25 August 2023 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of Fontan circulation on body composition and correlation with exercise capacity
thumbnail
Congress Presentation
Predictors of higher peak exercise oxygen uptake in a cohort of adult patients with the Fontan circulation
thumbnail
Congress Presentation
The impact of exercise training in Fontan procedure patients: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources